Comparison of Factor VIII Transgenes Bioengineered for Improved Expression in Gene Therapy of Hemophilia A

Overview

Journal Hum Gene Ther

Specialties Genetics
Pharmacology

Date 2009 Feb 19

PMID 19222367

Citations 21

Authors

Kerry L Dooriss

Gabriela Denning

Bagirath Gangadharan

Elisabeth H Javazon

David A McCarty

H Trent Spencer

Christopher B Doering

Affiliations

Soon will be listed here.

Abstract

Successful gene therapy of hemophilia A depends on the sustained expression of therapeutic levels of factor VIII (fVIII). Because of mRNA instability, interactions with resident endoplasmic reticulum (ER) chaperones, and the requirement for carbohydrate-facilitated transport from the ER to the Golgi apparatus, fVIII is expressed at much lower levels from mammalian cells than other proteins of similar size and complexity. A number of bioengineered forms of B domain-deleted (BDD) human fVIII have been generated and shown to have enhanced expression. Previously, we demonstrated that recombinant BDD porcine fVIII exhibits high-level expression due to specific sequence elements that increase biosynthesis via enhanced posttranslational transit through the secretory pathway. In the current study, high-expression recombinant fVIII constructs were compared directly in order to determine the relative expression of the various bioengineered fVIII transgenes. The data demonstrate that BDD porcine fVIII expression is superior to that of any of the human fVIII variant constructs tested. Mean fVIII expression of 18 units/10(6) cells/24 hr was observed from HEK-293 cells expressing a single copy of the porcine fVIII transgene, which was 36- to 225-fold greater than that of any human fVIII transgene tested. Furthermore, greater than 10-fold higher expression was observed in human cells transduced with BDD porcine fVIII versus BDD human fVIII-encoding lentiviral vectors, even at low proviral copy numbers, supporting its use over other human fVIII variants in future hemophilia A gene therapy clinical trials.

Citing Articles

Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII.

Ramamurthy R, Rodriguez M, Ainsworth H, Shields J, Meares D, Bishop C Front Immunol. 2023; 13:954984.

PMID: 36591257 PMC: 9800010. DOI: 10.3389/fimmu.2022.954984.

Identification of coagulation factor IX variants with enhanced activity through ancestral sequence reconstruction.

Knight K, Coyle C, Radford C, Parker E, Fedanov A, Shields J Blood Adv. 2021; 5(17):3333-3343.

PMID: 34477814 PMC: 8525220. DOI: 10.1182/bloodadvances.2021004742.

Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A.

Stem C, Rodman C, Ramamurthy R, George S, Meares D, Farland A Front Cell Dev Biol. 2021; 9:678117.

PMID: 34447745 PMC: 8383113. DOI: 10.3389/fcell.2021.678117.

Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency.

Cao W, Dong B, Horling F, Firrman J, Lengler J, Klugmann M Mol Ther Methods Clin Dev. 2020; 19:486-495.

PMID: 33313336 PMC: 7708868. DOI: 10.1016/j.omtm.2020.10.013.

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A.

El-Akabawy N, Rodriguez M, Ramamurthy R, Rabah A, Trevisan B, Morsi A Mol Ther Methods Clin Dev. 2020; 17:465-477.

PMID: 32258210 PMC: 7109377. DOI: 10.1016/j.omtm.2020.03.001.

References

Hong S, Hwang D, Yoon S, Isacson O, Ramezani A, Hawley R . Functional analysis of various promoters in lentiviral vectors at different stages of in vitro differentiation of mouse embryonic stem cells. Mol Ther. 2007; 15(9):1630-9. PMC: 2614215. DOI: 10.1038/sj.mt.6300251. View

Doering C, Gangadharan B, Dukart H, Spencer H . Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity. Mol Ther. 2007; 15(6):1093-9. DOI: 10.1038/sj.mt.6300146. View

Dwarki V, Belloni P, Nijjar T, Smith J, Couto L, RABIER M . Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice. Proc Natl Acad Sci U S A. 1995; 92(4):1023-7. PMC: 42629. DOI: 10.1073/pnas.92.4.1023. View

Ide L, Gangadharan B, Chiang K, Doering C, Spencer H . Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens. Blood. 2007; 110(8):2855-63. PMC: 2018667. DOI: 10.1182/blood-2007-04-082602. View

Matsui H, Shibata M, Brown B, Labelle A, Hegadorn C, Andrews C . Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Stem Cells. 2007; 25(10):2660-9. DOI: 10.1634/stemcells.2006-0699. View

Moussalli M, Pipe S, Hauri H, Nichols W, Ginsburg D, Kaufman R . Mannose-dependent endoplasmic reticulum (ER)-Golgi intermediate compartment-53-mediated ER to Golgi trafficking of coagulation factors V and VIII. J Biol Chem. 1999; 274(46):32539-42. DOI: 10.1074/jbc.274.46.32539. View

Kang Y, Xie L, Tran D, Stein C, Hickey M, Davidson B . Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. Blood. 2005; 106(5):1552-8. PMC: 1895217. DOI: 10.1182/blood-2004-11-4358. View

Vandendriessche T, Vanslembrouck V, Goovaerts I, Zwinnen H, Vanderhaeghen M, Collen D . Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc Natl Acad Sci U S A. 1999; 96(18):10379-84. PMC: 17896. DOI: 10.1073/pnas.96.18.10379. View

Saenko E, Ananyeva N, Shima M, Hauser C, Pipe S . The future of recombinant coagulation factors. J Thromb Haemost. 2003; 1(5):922-30. DOI: 10.1046/j.1538-7836.2003.00196.x. View

10.

Toole J, Pittman D, Orr E, Murtha P, Wasley L, Kaufman R . A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci U S A. 1986; 83(16):5939-42. PMC: 386412. DOI: 10.1073/pnas.83.16.5939. View

11.

Chang A, Stephan M, Sadelain M . Stem cell-derived erythroid cells mediate long-term systemic protein delivery. Nat Biotechnol. 2006; 24(8):1017-21. DOI: 10.1038/nbt1227. View

12.

Hanawa H, Hematti P, Keyvanfar K, Metzger M, Krouse A, Donahue R . Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood. 2004; 103(11):4062-9. DOI: 10.1182/blood-2004-01-0045. View

13.

Wu X, Li Y, Crise B, Burgess S . Transcription start regions in the human genome are favored targets for MLV integration. Science. 2003; 300(5626):1749-51. DOI: 10.1126/science.1083413. View

14.

Chao H, Mao L, Bruce A, Walsh C . Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood. 2000; 95(5):1594-9. View

15.

Kootstra N, Matsumura R, Verma I . Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Mol Ther. 2003; 7(5 Pt 1):623-31. DOI: 10.1016/s1525-0016(03)00073-x. View

16.

Schroder A, Shinn P, Chen H, Berry C, Ecker J, Bushman F . HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002; 110(4):521-9. DOI: 10.1016/s0092-8674(02)00864-4. View

17.

West A, Fraser P . Remote control of gene transcription. Hum Mol Genet. 2005; 14 Spec No 1:R101-11. DOI: 10.1093/hmg/ddi104. View

18.

Wirth D, Hauser H . Flp-mediated integration of expression cassettes into FRT-tagged chromosomal loci in mammalian cells. Methods Mol Biol. 2004; 267:467-76. DOI: 10.1385/1-59259-774-2:467. View

19.

Marquette K, Pittman D, Kaufman R . A 110-amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells. J Biol Chem. 1995; 270(17):10297-303. DOI: 10.1074/jbc.270.17.10297. View

20.

Chuah M, Collen D, Vandendriessche T . Preclinical and clinical gene therapy for haemophilia. Haemophilia. 2004; 10 Suppl 4:119-25. DOI: 10.1111/j.1365-2516.2004.00984.x. View